AstraZeneca 在某些内脏癌中 获得印度对Imfinzi的认可 AstraZeneca gets Indian approval for Imfinzi in certain endometrial cancers.

印度的AstraZeneca Pharma 印度已经获得印度CDSCO的批准,可以销售Imfinzi(durvalumab)与carboplatin和paclitaxel相结合的先进或常见子宫颈癌的一线治疗,以及作为不匹配修复缺陷(dMMMR)子宫颈癌患者的维持疗法。 AstraZeneca Pharma India has received approval from India’s CDSCO to market Imfinzi (durvalumab) for first-line treatment of advanced or recurrent endometrial cancer when combined with carboplatin and paclitaxel, and as maintenance therapy for patients with mismatch repair deficient (dMMR) endometrial cancer. 该药物有两个长处,经批准进口、销售和分销,等待最后法定批准。 The drug, available in two strengths, is approved for import, sale, and distribution pending final statutory clearances. 这一扩展为印度特定子宫颈癌患者提供了一种新的免疫治疗选择。 This expansion offers a new immunotherapy option for specific endometrial cancer patients in India.